Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201

Inclusion Criteria:

• Being clinically healthy
• Ability to voluntarily sign an informed consent form (ICF).
• Ability and willingness to comply with the scheduled visits according to theintervention plan and other procedures of the study.
• Age between 18 and 35.
• Absence of history of contact lens use.
• Women of childbearing age must agree to continue (starting ≥ 30 days previous to theICF) the use of a hormonal contraception method of a intrauterine device (IUD) duringthe period of the study.
• Best corrected visual acuity (BVCA) of at least 20/30 (logMAR 0.2) or better in botheyes.
• Best near corrected visual acuity (BNVCA) of at least 20/25 (logMAR 0.1) or better inboth eyes.
• Presenting vital signs within normal parameters.
• Presenting an IOP ≥10 and ≤ 21 mmHg

Exclusion Criteria:

• Using any kind of ophthalmic topical products.
• Presenting known allergy or intolerance to any ingrediente of atropine eyedrops or anyother derivatives of antimuscarinic agents.
• Using any medication of herbolary products (plant extracts, infusions, naturistpreparations, homeopathy, etc) through any route of administration
• For women: being pregnant, breastfeeding or planning to get pregnant during the periodof the study.
• Having participated in any clinical study 90 days prior to the inclusion in thisstudy.
• Having participated in this clinical study.
• Inability to follow the lifestyle considerations of this study.
• History of any chronic degenerative disease, including diabetes and hypertension.
• Presenting active inflammatory or infectious diseases when entering this study.
• Presenting unresolved lesions or trauma when entering this study.
• History of any ocular surgery.
• History of any surgery, non-ocular, within the previous 3 months of entering thisstudies.
• Being or having an direct family member (spouse, parent/legal guardian, sibling, etc)as employee of the investigation site or the sponsor, who participates directly inthis study. Elimination criteria:
• Withdraw of ICF.
• Adverse event, related or not to the investigation product, that according to theprincipal investigator and/or the sponsor may affect the integrity of the patient tocontinue safely with the study's procedures.
• Hypersensitivity or lack of tolerance to any of the ingredients used during thestudy's procedures (fluorescein, lissamine green, tetracaine, etc)
• Hypersensitivity or lack of tolerance to the investigation product.
• Presenting an adherence to treatment < 90%, as determined through the subjects diary.